oasis 1 oral semaglutide 50 mg obesity lancet 2023 taken once per day in adults with overweight or (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial Obesity: once-daily oral GLP-1 orforglipron

Weight loss medications have transformed obesity management over the last few years, with Semaglutide emerging as one of the most effective treatments

Nausea, vomiting, generalized weakness, and abdominal pain were the predominant symptoms reported

Various pre-clinical and clinical studies have revealed the hepatoprotective effect of semaglutide in NASH and neuroprotective effect in Parkinsons and Alzheimers disease

Studies addressing skeletal muscle quantity, quality, and functional capacity are needed to clarify the effects of GLP-1 RAs on sarcopenic obesity in older adults.

But theres a tradeoff

Singh G, Krauthamer M, Bjalme-Evans M